Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot

Last updated: October 12, 2010
Sponsor: Qingdao University
Overall Status: Trial Status Unknown

Phase

1/2

Condition

Peripheral Arterial Occlusive Disease

Diabetes And Hypertension

Claudication

Treatment

N/A

Clinical Study ID

NCT01216865
MSCDF001
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to determine whether umbilical cord Mesenchymal Stem Cells of treatment for diabetic foot is safe and effective in the management of diabetic foot ischemia, the therapeutic effect of stem cells is caused by improving blood circulation in ischemic limb which would in turn promote ulcer healing, prevent amputation of limb and relieve the Sevier pain of ischemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diabetes mellitus Type 2

  • Age 18 - 75 years

  • Subject has an Ankle-brachial index < 0.9

  • Subject has had previous conservative treatment which resulted in little or noimprovement

  • Subject has had no stem cell treatment within the past 6 months

  • No sufficient response to best standard care delivered for six weeks.

  • No surgical or radiological interventional option for revascularisation as confirmedby a vascular surgeon and an interventional radiologist

  • Signed informed consent

  • Absence of life-threatening complications from the ischemic limb

  • Life expectancy more than 2 years

  • Negative pregnancy test when applicable

Exclusion

Exclusion Criteria:

  • Diabetic retinopathy

  • History of neoplasm or hematological disease

  • Uncontrolled high blood pressure (>180/110)

  • Severe cardiac insufficiency (New York Heart Association [NYHA] IV) or ejectionfraction<30%

  • Malignant ventricular arrythmia

  • Deep venous thrombosis during the last 3 months

  • Active bacterial infection

  • Body mass index > 35 Kg/m2

  • Stroke or myocardial infarction during the last 3 months

Study Design

Total Participants: 50
Study Start date:
January 01, 2011
Estimated Completion Date:
July 31, 2013

Study Description

Type 2 diabetic patients with diabetic foot were enrolled and randomized to either transplanted group or control group. Patients in transplanted group received the stem cells treatment,Patients in control group received the standard treatment. After culture in vitro, umbilical cord mesenchymal stem cells should go through safety evaluation which include culture and check of pathogenic microorganisms (bacteria, mycoplasma, chlamydia, eumycete and viruses) of the cells medium and karyotype analysis of the mesenchymal stem cells. Only the safe cells were harvested and transplanted by multiple intramuscular injections into the impaired lower limbs. Follow-up index include: efficacy (pain,ulcer healing rate, lower limb amputation rate and ,ankle-brachial index,magnetic resonance angiography,electromyogram) and safety (infection of the injection site, fever, and tumour generation).

Connect with a study center

  • Stem Cell Research Center of Medical School Hospital of Qingdao University

    Qingdao, Shandong 266003
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.